EX-FILING FEES 5 tm258031d2_ex-filingfees.htm EX-FILING FEES

 

Exhibit 107

 

Calculation of Filing Fee Tables
Post-Effective Amendment No. 1 to Form 
S-3
(Form Type)
Editas Medicine, Inc.
(Exact Name of Registrant as Specified in its 
Charter)
Table 1: Newly Registered and Carry Forward Securities

 

  Security
Type
Security
Class
Title

Fee

Calculation

or Carry

Forward

Rule

Amount

Registered

Proposed

Maximum

Offering

Price Per

Unit

Maximum

Aggregate

Offering
Price

Fee
Rate

Amount of

Registration

Fee

Carry

Forward

Form

Type

Carry

Forward

File

Number

Carry

Forward

Initial

Effective

Date

Filing Fee

Previously

Paid In

Connection

with

Unsold

Securities

to be

Carried

Forward

Newly Registered Securities

 Fees to Be 

Paid

Debt Debt Securities (1) (1) (1) (1) (1) (1)

 Fees to Be 

Paid

Equity Common Stock, par value $0.0001 per share (1) (1) (1) (1) (1) (1)

Fees to Be 

Paid

Equity Preferred Stock, par value $0.0001 per share (1) (1) (1) (1) (1) (1)

 Fees to Be 

Paid

Other Depositary Shares (2) (1) (1) (1) (1) (1) (1)

Fees to Be 

Paid

Other Subscription Rights (3) (1) (1) (1) (1) (1) (1)

Fees to Be 

Paid

Other Purchase Contracts (4) (1) (1) (1) (1) (1) (1)

 Fees to Be 

Paid

Other Warrants (5) (1) (1) (1) (1) (1) (1)

Fees to Be 

Paid

Other Units (6) (1) (1) (1) (1) (1) (1)

Fees to Be 

Paid

Unallocated (Universal) Shelf  Unallocated (Universal) Shelf 457(o) (1) (1) $50,455,118.56 0.00015310 $7,724.68

Fees 

Previously 

Paid 

Equity Common Stock, par value $0.0001  per share 457(o) (7) (7) $299,544,881.44 $32,680.34
Carry Forward Securities

Carry

Forward

 Securities

$350,000,000 (1) 
  Total Offering Amounts       $40,405.02        
  Total Fees Previously Paid       $32,680.34(7)         
  Total Fee Offsets       —         
  Net Fee Due       $7,724.68        

 

 

 

 

(1)Pursuant to Instruction 2.A(iii)(b) of Item 16(b) of Form S-3, this information is not required to be included. An indeterminate amount of the securities of each identified class is being registered as may from time to time be offered under this registration statement at indeterminate prices, along with an indeterminate number of securities that may be issued upon exercise, settlement, exchange or conversion of securities offered or sold under this registration statement, as shall have an aggregate initial offering price up to $350,000,000. The securities registered pursuant to this registration statement include unsold securities previously registered on this registration statement on February 28, 2024 (the “Original Registration Statement”). The Original Registration Statement registered the offer and sale of up to $300,000,000 in shares of the registrant’s common stock that may have been issued and sold under a sales agreement with TD Securities (USA) LLC (as successor to Cowen and Company, LLC), as amended. The registrant previously paid a fee of $32,730.00 related to such $300,000,000 in shares of common stock. Of such shares of common stock, $299,544,881.44 remain unsold (the “Unsold Shelf Securities”). The registrant has determined to include in this registration statement all of the Unsold Shelf Securities. Pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities. Separate consideration may or may not be received for securities that are issuable upon conversion, exercise or exchange of other securities.

 

(2)Each depositary share will be issued under a deposit agreement, will represent an interest in a fractional share or multiple shares of preferred stock and will be evidenced by a depositary receipt.

 

(3)The subscription rights to purchase shares of common stock or preferred stock will be offered without additional consideration.

 

(4)Each purchase contract will be issued under a purchase agreement and will obligate holders to purchase from or sell to Editas Medicine, Inc. and obligate Editas Medicine, Inc. to sell to or purchase from the holders, a specified number of shares of common stock, preferred stock or depositary shares.

 

(5)The warrants covered by this registration statement may be warrants for common stock, preferred stock, depositary shares or debt securities.

 

(6)Units may be issued under a unit agreement and will represent an interest in one or more securities registered under this registration statement including shares of common stock or preferred stock, debt securities, depositary shares or warrants, in any combination, which may or may not be separable from one another.

 

(7)The Net Fee Due relates to the additional $50,455,118.56 of securities to be sold by the registrant registered hereunder. As a result, a registration fee of $7,724.68 is being paid herewith.